Mauritian cynomolgus macaques

Mauritian-origin cynomolgus macaques (MCM) were purchased from a commercial vendor following serological testing confirming the absence of antibodies to influenza A and B viruses (Supplementary Table ¹). MCM were split randomly into three experimental groups based on sex to yield equal numbers of male and female MCM in each group. All MCM were less than four years of age. MCM were moved to Tulane National Primate Research Center (TNPRC) for the vaccine phase of the project, which was reviewed and approved by the institutional Animal Care and Use Committee of Tulane University. Animals were cared for in accordance with the Guide for the Care and Use of Laboratory Animals. Procedures for handling and ABSL2 containment of animals were approved by the Tulane University Institutional Biosafety Committee. The TNPRC is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International. Challenge of the MCM was performed at the University of Pittsburgh, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Prior to challenge, the work with animals described in this report was approved by the University of Pittsburgh’s Institutional Animal Care & Use Committee (IACUC). CyCMV vectors were delivered subcutaneously at 1 × 10⁷ PFU per vector.